Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 16/20 | 0.53 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20420160 | 1.00 | TACR1 (0.53) | TACR1PRKG1HTR2AHTR2CHTR2B | |
| SCHEMBL20400483 | 1.00 | TACR1 (0.53) | TACR1PRKG1HTR2AHTR2CHTR2B | |
| SCHEMBL705293 | 1.00 | TACR1 (0.53) | TACR1PRKG1HTR2AHTR2CHTR2B | |
| SCHEMBL705965 | 0.87 | TACR1 (0.69) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL706948 | 0.86 | TACR1 (0.47) | TACR1PRKG1HTR2AHTR2CHTR2B | |
| SCHEMBL706947 | 0.86 | TACR1 (0.47) | TACR1PRKG1HTR2AHTR2CHTR2B | |
| SCHEMBL706946 | 0.86 | TACR1 (0.47) | TACR1PRKG1HTR2AHTR2CHTR2B | |
| SCHEMBL13377999 | 0.82 | TACR1 (0.74) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL13378008 | 0.82 | TACR1 (0.74) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL2894433 | 0.82 | TACR1 (0.49) | TACR1PRKG1CYP3A4CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180235931-A1 | USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES | MENLO THERAPEUTICS INC. | 2018-08-23 | — | — | US | disclosed |
| EP-2144503-B9 | 4-(octahydro-2H-isoindol-2-yl)-1,3-oxazol-4-one as TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2144503-B1 | 4-(octahydro-2H-isoindol-2-yl)-1,3-oxazol-4-one as TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8124633-B2 | Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, HTR1D, TACR2 | TACR1 1/4885PRKG1 1538/4885HTR2A 39/4885 |
| US-20180235931-A1 | USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES | OPRK1, TAC3, BRS3 | TACR1 9/4885PRKG1 230/4885HTR2A 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.